Staff Directory
Academic Qualification
- Master of Internal Medicine - Masters Degree (Clinical Specialist), Universiti Malaya (UM)
- Ijazah Sarjana Muda Perubatan dan Sarjana Muda Pembedahan (MBBS) - Masters Degree, Universiti Malaya (UM)
How Soon Hin (Prof. Dr.)
Professor
IIUM Kuantan Campus
KULLIYYAH OF MEDICINE
joanchua@iium.edu.my
4719
Expert Profile
Dr How Soon Hin graduated from University of Malaya, Kuala Lumpur in 1996 and obtained his Master in Internal Medicine at the same university in 2002. He is currently working as Professor of Medicine, Kulliyyah of Medicine, International Islamic University and also serves as a consultant general physician and chest physician in Hospital Tengku Ampuan Afzan, Jalan Tanah Putih, 25100, Kuantan, Pahang (HTAA).
He has special interests in EBUS-TBNA, rigid bronchoscopy, metallic and silicone stenting, laser, endobronchial tumour debulking etc. His research interests are in melioidosis and lung cancer and he has published more than 55 papers in both local and international journals, and presented more than 80 abstracts at both local and international scientific meetings.
He has special interests in EBUS-TBNA, rigid bronchoscopy, metallic and silicone stenting, laser, endobronchial tumour debulking etc. His research interests are in melioidosis and lung cancer and he has published more than 55 papers in both local and international journals, and presented more than 80 abstracts at both local and international scientific meetings.
Area of Specialisation
- Medical And Health ~ Medical And Health Sciences ~ Biomedical Sciences ~ Other Biomedical Sciences n.e.c. - Consultant Physician and Chest Physician
Professional Membership
- 2009 - 2011: Member of Profesional Body / Association, Malaysia COPD Clinical Practise Guideline
Teaching Responsibilities
BODY REACTION TO PHYSICAL, CHEMICAL & BIOLOGICAL AGENTS | 2010/2011 |
CARDIOVASCULAR, RESPIRATORY AND HAEMOPOIETIC SYSTEMS | 2022/2023 |
CARDIOVASCULAR, RESPIRATORY, BLOOD AND BLOOD FORMING ORGANS | 2010/2011 |
ELEMENTARY CLINIC | 2023/2024 2022/2023 2021/2022 |
GENERAL MEDICAL SPECIALTY/GENERAL MEDICAL POSTING | 2021/2022 2020/2021 2019/2020 |
General Medicine | 2013/2014 |
GENERAL MEDICINE & GENERAL SURGERY | 2023/2024 2022/2023 2021/2022 2020/2021 2019/2020 |
GENERAL MEDICINE I | 2024/2025 2023/2024 2022/2023 |
GENERAL MEDICINE II & SUBSPECIALTY POSTING II | 2024/2025 2023/2024 2022/2023 |
GENERAL MEDICINE/CCU/HDW/A&EPOSTING | 2022/2023 2021/2022 2020/2021 2019/2020 |
INTERNAL MEDICINE I | 2023/2024 2022/2023 2021/2022 2020/2021 2019/2020 2018/2019 2017/2018 2015/2016 2014/2015 2013/2014 2012/2013 2011/2012 2010/2011 |
INTERNAL MEDICINE II | 2023/2024 2022/2023 2021/2022 2020/2021 2019/2020 2018/2019 2017/2018 2016/2017 2015/2016 2014/2015 2013/2014 2012/2013 2011/2012 2010/2011 |
Respiratory and Gastrointestinal Systems Pharmacology | 2023/2024 |
SPECIALIZED POSTING | 2021/2022 2020/2021 |
SUBSPECIALTY POSTING I | 2024/2025 2023/2024 |
SURGERY, TRAUMA AND CRITICAL CARE | 2012/2013 2011/2012 |
Supervision
Development Of A Wireless Parallel Interdigitated Electrode Biosensing System For Monitoring Cancer Cells Treatment.
Ph.D
Completed
2024
Co-supervisor
|
Characterization Of Potential Burkholderia Pseudomallei Protein Biomarkers In Urine Of Acute Melioidosis Cases In Pahang, Malaysia.
Ph.D
Completed
2021
Co-supervisor
|
A Study On Treatment Outcomes For Advanced Epidermal Growth Factor Receptor (Egfr)-Positive Non-Small Cell Lung Cancer Patients On Tyrosine Kinase Inhibitors (Tki) As A First-Line Treatment.
Master
Completed
2023
Main Supervisor
|
Systematic Review On First Line Treatment For Advanced Non-Small Cell Lung Carcinoma Without Driver Mutation: Role Of Immunotherapy
.
Master
Completed
2022
Main Supervisor
|
Prediction Of Cancer Associated Thrombosis Among Malaysian Population Using Multiple Risk Assessment Model (Comparative Study).
Master
Completed
2021
Main Supervisor
|
Survival Of Lung Cancer Patient And Its Prognostic Factor In A Single Centre At Hospital Tengku Ampuan Afzan, Kuantan Pahang, Malaysia 2020.
Master
Completed
2020
Main Supervisor
|
The Use Of Active Melioidosis Detect Tm In Early Diagnosis Of Melioidosis In Hospital Tengku Ampuan Afzan And Hospital Sultanah Nurzahirah.
Master
Completed
2019
Main Supervisor
|
Depressive Symptoms In Newly Diagnosed Lung Carcinoma: Prevalence And Associated Risk Factors
.
Master
Completed
2017
Main Supervisor
|
Dynamics Of Serological And Bacterial Responses Among Patients With Melioidosis.
Master
Completed
2016
Co-supervisor
|
The Use Of Multiplex Real-Time Pcr For Differential Detection Of Streptococcus Pneumoniae Bacterial Pathogoens In Respiratory And Blood Samples Of Patients With Community Acquired Pneumonia.
Master
Completed
2010
Co-supervisor
|
The Evaluation Of Indirect Immunofluorescent Test (Ifat) And Lipopolysaccharide Polymerase Chain Reaction (Lps-Pcr).
Master
Completed
2008
Co-supervisor
|
Tbd.
Master
In Progress
Main Supervisor
|
Tbd.
Master
In Progress
Main Supervisor
|
Research Projects
Completed
2021 - 2023 | Polymerase Chain Reaction (Pcr) Versus Blood Culture To Detect Burkholderia Pseudomallei Species In High Risk Patients With Suspected Or Diagnosed With Melioidosis In Pahang |
2016 - 2019 | Development of a Parallel biosensing system for personalized and pointof-care chemotherapy treatment |
2010 - 2013 | The Use of Multiplex Real-Time PCR for Differential Detection of Streptococcus Pneumoniae, Burkholderia pseudomallei and Atypical Bacterial Pathogens in Respiratory and Blood Samples of Patients with Community Acquired Pneumonia |
2008 - 2010 | Treatment Compliance among Lung Cancer Patient in Malaysia |
2007 - 2014 | Characterization of Burkholderia Pseudomallei and Evaluation and Modification of Available Serodiagnostic Tests for Melioidosis |
2007 - 2014 | Osteoporosis in Asthmatic Patients on Inhaled Corticosteroids |
2006 - 2008 | Monitoring Treatment Response of Patients With Smear Positive Pulmonary Tuberculosis |
2004 - 2006 | The Study of Musculoskeletal Meliodosis in Pahang |
2004 - 2006 | Study of Lung Function Among Traffic Police in Kuantan |
2004 - 2017 | Survey of Physicians and Patients on Awareness of Patients Rights, Attitudes, Practices and Role of Spirituallity and Holistic Medicine |
On-Going
2022 - Present | Use of Interleukin-8 as a biomarker of predicting response to immunotherapy in advanced non-small cell lung cancer |
2022 - Present | IIUM Health, Safety and Environment Unit (IHSEN) |
2021 - Present | Polymerase Chain Reaction (PCR) Versus Blood Culture to Detect Burkholderia Pseudomallei Species in High Risk Patients with Suspected or Diagnosed with Melioidosis in Pahang |
2011 - Present | One Best Answer - Internal Medicine |
2010 - Present | Identification of Epidermal Growth Factor Receptor Mutation of Lung Cancer Patients in Malaysia |
2010 - Present | Community-acquired Pneumonia in Hospital Tengku Ampuan Afzan, Kuantan |
2008 - Present | The Use of An Air-Sealed Bag in Spontanoues Pneumothorax |
- | 24. A randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 48 weeks of once daily treatment of orally inhaled BI 1744 CL (5 ?g [2 actuations of 2.5 ?g] and 10 ?g [2 actuations of 5 ?g]) delivered by the Respimat? Inhaler, and 48 weeks of twice daily Foradil? (12 ?g) delivered by the Aerolizer? Inhaler, in patients with Chronic Obstructive Pulmonary Disease (COPD) |
- | 23. A comparison of Symbicort? Maintenance and Reliever Therapy (Symbicort Turbuhaler? 160/4.5ug, one inhalation bid plus as needed) and Symbicort Turbuhaler 160/4.5ug, one inhalation bid plus terbutaline Turbuhaler 0.4 mg/inhalation as needed, for treatment of asthma - a 12-month, randomized, double-blind, parallel group, active-controlled, multinational, phase III study in asthmatic patients aged 16 years and above. |
- | 18. International, multi-center, randomized, double blind study to compare the overall mortality in acutely ill medical patients treated with enoxaparin versus placebo in addition to Graduated Elastic Stokings |
- | A phase 2/3 trial to assess the safety, immunogenicity and premalinary efficacy of recombinant human EGF-rP64K/ Montanide ISA 51 Vaccine administered to patients with NSCLC after receiving conventional first line chemotherapy. |
Award & Recognition
06 Jul, 2012 | Best Poster Presentation - Malaysian Thoracic Society | National |
23 Jul, 2010 | Best Poster Presentation - Malaysian Thoracic Society | National |
23 Jul, 2010 | 2nd best oral presentation - Malaysian Thoracic Society | National |
12 Apr, 2006 | Promising Reseachers Award - IIUM | University |
16 Jul, 2004 | Best Oral presentation - Malaysian Thoracic Society | National |